Nanoviricides, Inc. (NNVC): Shareholders' Equity
$8.68M
As of 2026-06-30
-16.4%
3-year compound annual growth
-21.9%
5-year compound annual growth
-9.3%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $8.68M | +15.5% | 2026-09-28, Balance as of period end |
| 2025-06-30 | $7.52M | -34.4% | 2026-09-28, Balance as of period end |
| 2024-06-30 | $11.46M | -22.9% | 2025-09-29, Balance as of period end |
| 2023-06-30 | $14.87M | -35.6% | 2024-09-27, Balance as of period end |
| 2022-06-30 | $23.08M | -22.8% | 2023-10-13, Balance as of period end |
| 2021-06-30 | $29.91M | +37.5% | 2022-10-13, Balance as of period end |
| 2020-06-30 | $21.76M | +105.3% | 2021-10-12, Balance as of period end |
| 2019-06-30 | $10.60M | -40.0% | 2021-10-12, Balance as of period end |
| 2018-06-30 | $17.66M | -13.1% | 2020-10-13, Balance as of period end |
| 2017-06-30 | $20.32M | -11.8% | 2019-08-23, Balance as of period end |
| 2016-06-30 | $23.05M | -27.5% | 2018-10-12, Balance as of period end |
| 2015-06-30 | $31.79M | +36.0% | 2017-09-28, Balance as of period end |
| 2014-06-30 | $23.37M | +191.8% | 2016-09-16, Balance as of period end |
| 2013-06-30 | $8.01M | -42.2% | 2015-09-14, Balance as of period end |
| 2012-06-30 | $13.85M | +36.2% | 2015-02-23, Balance as of period end |
| 2011-06-30 | $10.17M | +56.0% | 2013-10-08, Balance as of period end |
| 2010-06-30 | $6.52M | +162.3% | 2013-10-08, Balance as of period end |
| 2009-06-30 | $2.49M | +460.1% | 2013-10-08, Balance as of period end |
| 2008-06-30 | $443.7K | -11.3% | 2013-10-08, Balance as of period end |
| 2007-06-30 | $500.3K | -59.6% | 2013-10-08, Balance as of period end |
| 2006-06-30 | $1.24M | n/m | 2013-10-08, Balance as of period end |
| 2005-06-30 | -$66.0K | n/a | 2013-10-08, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Nanoviricides, Inc. (NNVC) | 2026-06-30 | $8.68M | +15.5% |
| Abbott Laboratories (ABT) | 2025-12-31 | $52.13B | +9.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $18.47B | +13.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $26.88M | -1.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $26.54B | +85.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $86.78B | -1.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $81.54B | +14.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $161.55M | +0.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $52.66B | +13.6% |
Compare NNVC, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗